Drug intelligence / Profile preview

BR-3006

Development stage: Unknown
Lead developer: Boryung
Modality: Small Molecules
Administration: Oral

Overview

BR-3006 is an investigational small molecule drug developed by Boryung Corp. It is being studied primarily for the treatment of type 2 diabetes and other endocrinology and metabolic diseases. The drug has been evaluated in multiple Phase 1 clinical trials, including studies assessing its pharmacokinetics, safety, and potential drug-drug interactions in healthy volunteers under both fed and fasting conditions. As of June 2025, no detailed mechanism of action or specific molecular target has been disclosed publicly for BR-3006[2][3]. The compound is administered orally[3].

Other names: BR3006BR-3006BR 3006

Beyond the preview

Go deeper on BR-3006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BR-3006.

Explore the full profile